The spike protein of SARS-CoV--a target for vaccine and therapeutic development.
The spike protein of SARS-CoV--a target for vaccine and therapeutic development.
复制标题
DOI：
10.1038/nrmicro2090
复制
发表时间：
2009-03
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
本文综述了严重急性呼吸综合征冠状病毒（SARS- cov）刺突(S)蛋白作为预防和治疗SARS疫苗和治疗药物的靶点的研究进展。SARS是一种新出现的传染病，由SARS- cov引起，SARS是一种导致全球SARS爆发的新型冠状病毒。SARS-CoV S蛋白介导病毒与其受体血管紧张素转换酶2的结合，促进病毒与宿主细胞膜的融合和病毒进入宿主细胞。SARS-CoV S蛋白诱导针对SARS-CoV的体液和细胞免疫应答。SARS S蛋白是新型SARS疫苗的靶点。这些疫苗基于SARS-CoV全长S蛋白及其受体结合域，包括基于DNA、病毒载体和亚基的疫苗。多肽、抗体、有机化合物和短干扰rna是针对S蛋白的额外抗SARS-CoV治疗方法。基于SARS-CoV S蛋白的疫苗和药物的工作将有助于为开发针对其他可引起新发传染病的I类融合蛋白病毒的预防策略和治疗方法提供模型。2002年至2004年间爆发的严重急性呼吸系统综合症（SARS）导致数百人死亡。针对SARS冠状病毒（SARS- cov）的疫苗可以在未来疫情期间保护人群。在这篇综述中，蒋世波和他的同事描述了这些基于sars冠状病毒刺突蛋白的疫苗以及其他治疗方法。严重急性呼吸系统综合征（SARS）是一种由新型冠状病毒SARS-冠状病毒（SARS- cov）引起的新型传染病。sars冠状病毒刺突(S)蛋白由两个亚基组成；S1亚基包含与宿主细胞受体血管紧张素转换酶2结合的受体结合域，S2亚基介导病毒与宿主细胞膜的融合。在感染SARS-CoV期间，S蛋白在诱导中和抗体和t细胞反应以及保护性免疫中起关键作用。在这篇综述中，我们重点介绍了基于S蛋白的疫苗和治疗方法的最新进展。
This Review provides an overview on the spike (S) protein of severe acute respiratory syndrome-coronavirus (SARS-CoV) as a target for the development of vaccines and therapeutics for the prevention and treatment of SARS. SARS is a newly emerging infectious disease, caused by SARS-CoV, a novel coronavirus that caused a global outbreak of SARS. SARS-CoV S protein mediates binding of the virus with its receptor angiotensin-converting enzyme 2 and promotes the fusion between the viral and host cell membranes and virus entry into the host cell. SARS-CoV S protein induces humoral and cellular immune responses against SARS-CoV. SARS S protein is the target of new SARS vaccines. These vaccines are based on SARS-CoV full-length S protein and its receptor-binding domain, including DNA-, viral vector- and subunit-based vaccines Peptides, antibodies, organic compounds and short interfering RNAs are additional anti-SARS-CoV therapeutics that target the S protein. The work on SARS-CoV S protein-based vaccines and drugs will be useful as a model for the development of prophylactic strategies and therapies against other viruses with class I fusion proteins that can cause emerging infectious diseases. The outbreaks of severe acute respiratory syndrome (SARS) between 2002 and 2004 killed hundreds of people. Vaccines against the SARS coronavirus (SARS-CoV) could protect the population during future outbreaks. In this Review, Shibo Jiang and colleagues describe such vaccines, as well as other therapeutics, based on the SARS-CoV spike protein. Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease caused by a novel coronavirus, SARS-coronavirus (SARS-CoV). The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV. In this Review, we highlight recent advances in the development of vaccines and therapeutics based on the S protein.
登录
查看更多内容
影响因子：
6
作者：
Greenough, TC;Carville, A;Coderre, J;Somasundaran, M;Sullivan, JL;Luzuriaga, K;Mansfield, K
通讯作者：
Mansfield, K
影响因子：
5.4
作者：
Bosch, Berend Jan;Bartelink, Willem;Rottier, Peter J. M.
通讯作者：
Rottier, Peter J. M.
影响因子：
7.6
作者：
Akerström S;Mirazimi A;Tan YJ
通讯作者：
Tan YJ
影响因子：
3.7
作者：
Coughlin M;Lou G;Martinez O;Masterman SK;Olsen OA;Moksa AA;Farzan M;Babcook JS;Prabhakar BS
通讯作者：
Prabhakar BS
影响因子：
4.4
作者：
Dutta, Noton Kumar;Mazumdar, Kaushiki;Park, Jae-Hak
通讯作者：
Park, Jae-Hak